Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


Our top-notch dedicated system is used to design specialised libraries for receptors.


 

Fig. 1. The screening workflow of Receptor.AI

This process includes extensive molecular simulations of the receptor in its native membrane environment, along with ensemble virtual screening that accounts for its conformational mobility. In the case of dimeric or oligomeric receptors, the entire functional complex is modelled, identifying potential binding pockets on and between the subunits to encompass all possible mechanisms of action.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q14833

UPID:
GRM4_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
Q14833; B3KVL9; B7Z1T9; B7Z1U6; F5GXM5; Q5SZ84; Q6ZMQ2

BACKGROUND:
Metabotropic Glutamate Receptor 4, identified by the accession number Q14833, is crucial for glutamate-mediated signaling in the central nervous system. It functions by binding glutamate, which triggers a signaling cascade through G proteins, ultimately affecting adenylate cyclase activity.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Metabotropic Glutamate Receptor 4 offers promising avenues for drug discovery, particularly in treating conditions related to neurotransmitter imbalances. Its unique role in modulating neuronal signaling underscores its therapeutic potential.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.